M
Mitsumasa Kishimoto
Researcher at Kyorin University
Publications - 131
Citations - 2361
Mitsumasa Kishimoto is an academic researcher from Kyorin University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 91 publications receiving 1454 citations. Previous affiliations of Mitsumasa Kishimoto include International University, Cambodia.
Papers
More filters
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
Désirée van der Heijde,In-Ho Song,Aileen L. Pangan,Atul Deodhar,Filip Van den Bosch,Walter P. Maksymowych,Tae-Hwan Kim,Mitsumasa Kishimoto,Andrea Everding,Yunxia Sui,X. Wang,Alvina D. Chu,Joachim Sieper +12 more
TL;DR: Upadacitinib 15 mg was efficacious and well tolerated in patients with active ankylosing spondylitis who had an inadequate response or contraindication to non-steroidal anti-inflammatory drugs, and these data support the further investigation of upadac itinib for the treatment of axial spondyoarthritis.
Journal ArticleDOI
Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study
Anna Molto,Adrien Etcheto,Désirée van der Heijde,Robert Landewé,Filip Van den Bosch,Wilson Bautista Molano,Rubén Burgos-Vargas,Peter P. Cheung,Eduardo Collantes-Estevez,Atul Deodhar,Bassel Elzorkany,Shandor Erdes,Jieruo Gu,Najia Hajjaj-Hassouni,Uta Kiltz,Tae-Hwan Kim,Mitsumasa Kishimoto,Shue Fen Luo,Pedro Machado,Pedro Machado,Walter P. Maksymowych,José A. Maldonado-Cocco,Helena Marzo-Ortega,Carlomaurizio Montecucco,Salih Ozgocmen,Floris A. van Gaalen,Maxime Dougados +26 more
TL;DR: Rigorous application of systematic evaluation of comorbidities may permit earlier detection of previously unknown risk factors, which may ultimately result in an improved outcome of patients with SpA.
Journal ArticleDOI
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
Jeff Greenberg,George W. Reed,Dennis Decktor,Leslie R. Harrold,Daniel E. Furst,Allan Gibofsky,Ralph Dehoratius,Mitsumasa Kishimoto,Joel M. Kremer,Corrona Investigators +9 more
TL;DR: No differences in rates of drug response or remission were observed among the three anti-TNF agents, and infliximab was associated with greater persistence in biologically naive patients.
Journal ArticleDOI
Reactive arthritis after COVID-19 infection.
Keisuke Ono,Mitsumasa Kishimoto,Teppei Shimasaki,Hiroko Uchida,Daisuke Kurai,Gautam A. Deshpande,Yoshinori Komagata,Shinya Kaname +7 more
TL;DR: The first case of ReA after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is reported, in a male patient who was admitted with COVID-19 pneumonia and subsequently completing a 14-day course of favipiravir.